ライフサイエンスコーパス: confidence limit

1 4 degrees C from 1981-2000 to 2091-2100 (90% confidence limits).

2 rom about 6.4 degrees C to 14 degrees C (90% confidence limits).

3 e-dependent changes in expression at the 99% confidence limit.

4 onent was dependent on cell cycle at the 99% confidence limit.

5 did not change significantly within the 95% confidence limit.

6 (EPA), but overlaps EPA's reported upper 95% confidence limit.

7 e interactions were resolved with acceptable confidence limits.

8 l sensitivity losses exceeded the normal 95% confidence limits.

9 individual macrobeads and by using binomial confidence limits.

10 tivity and specificity for each test and 95% confidence limits.

11 p < 0.001), with minimal bias and narrow 95% confidence limits.

12 of APOE genotypes to be assessed with useful confidence limits.

13 heir precision, usually given in the form of confidence limits.

14 re achieved with bootstrap to define the 95% confidence limits.

15 antile regression showed modestly smaller MD confidence limits.

16 7% vs 5%, p=0.75, OR estimate 1.44, 95% Wald confidence limits 0.23-7.85).

17 e interrater reliability was 0.45 (upper 95% confidence limit = 0.58).

18 ty by the same assessors was 0.54 (upper 95% confidence limit = 0.77); the interrater reliability was

19 42 (23.6%) did not (kappa = 0.828; lower 95% confidence limit = 0.790).

20 demonstrated excellent (r = 0.956, lower 90% confidence limit = 0.948; kappa = 0.73, 95% confidence i

21 nt encounters was high (r = 0.964, lower 90% confidence limit = 0.950; kappa = 0.80, 95% confidence i

22 association between PFS and OS was 0.30 (95% confidence limits = 0.26, 0.32).

23 sfusion (p = 0.06, relative risk = 1.90, 95% confidence limits = 0.95-3.78).

24 HCoV infection than with LDI (OR, 0.27 [95% confidence limit, 0.13-0.58]).

25 .10), and increased lactate (0.6 mmol/L [95% confidence limit, 0.3, 0.8]; p(group) < 0.0001) compared

26 of within-couple HIV transmission (upper 95% confidence limit, 0.30/100 couple-years of follow-up).

27 when compared with the third trimester (95% confidence limits, 0.36 to 2.81) (both P < 0.001).

28 sted long-term survival (hazard ratio, 0.64; confidence limits, 0.50 to 0.83; P=0.0005).

29 The hazard ratio for death was 0.72 (confidence limits, 0.51 to 1.01) in the conservative str

30 sk reduction of 33% (hazard ratio, 0.67; 95% confidence limits, 0.55, 0.81; P<0.0001), whereas those

31 ays was 88%, with a kappa value of 0.75 (95% confidence limits, 0.73 to 0.76).

32 higher HDLc showed no benefit (RR, 1.06; 95% confidence limits, 0.88, 1.27; P=0.53).

33 ival hazard ratio of 0.98 per unit increase (confidence limits, 0.97 to 0.98; P<0.0001).

34 d a free energy of 8.3 kcal/mol with tighter confidence limits, +0.5/-0.8 kcal/mol.

35 physician and patient was poor at 0.14 (95% confidence limit, -0.01 to 0.30) for simple kappa and 0.

36 reat analysis (risk difference, 0.023; 97.5% confidence limit, -0.061).

37 col analysis (risk difference, -0.016; 97.5% confidence limit, -0.087).

38 ectively; difference, 2.9; lower 1-sided 95% confidence limit, -0.1; P < .001 for noninferiority).

39 sal pH (mean difference, 0.015 pH units; 95% confidence limits, -0.054, 0.084).

40 imits, -0.68, 1.79) and -0.018 pH units (95% confidence limits, -0.069, 0.032) for "fresh" red cells

41 limits, -0.6, 1.64) and -0.033 pH units (95% confidence limits, -0.080, 0.129) for "stored" red cells

42 032) for "fresh" red cells and 0.52 kPa (95% confidence limits, -0.6, 1.64) and -0.033 pH units (95%

43 amucosal pH, respectively, was 0.56 kPa (95% confidence limits, -0.68, 1.79) and -0.018 pH units (95%

44 dose (SYNERGY, difference -0.06, upper 95.2% confidence limit: 0.02, p for noninferiority <0.001; SYN

45 RGY half dose, difference -0.03, upper 95.2% confidence limit: 0.05, p for noninferiority <0.001).

46 by the 2.5-fold wider confidence limits (95% confidence limits: 0.06, 0.43).

47 prior 2 years with no therapy was 0.36 (95% confidence limits: 0.21, 0.61).

48 e anemia (hemoglobin < 70 g/L) was 0.77 (95% confidence limits: 0.39, 1.51) in the twice-yearly dewor

49 patency of ITA grafts (odds ratio: 0.63; 95% confidence limits: 0.43 to 0.91; p = 0.013), but late pa

50 ed with DSA production (risk ratio 0.92 [95% confidence limits: 0.85, 0.99], and 0.70 [0.49, 1.00]).

51 e mix-adjusted death risk ratio of 0.90 (95% confidence limits: 0.86, 0.95; P < 0.001), whereas those

52 otene supplements with placebo was 1.10 (95% confidence limits: 0.89, 1.36; P = 0.39).

53 ty COMT diplotypes (hazard ratio = 1.42; 95% confidence limits: 0.96, 2.09).

54 % confidence limits 1.3 to 2.6) and 1.4 (95% confidence limits 1.0 to 2.0), respectively.

55 e lethal alleles per individual are 1.9 (95% confidence limits 1.3 to 2.6) and 1.4 (95% confidence li

56 using the F-wave (regression slope 2.33, 95% confidence limits 1.30-3.36).

57 combined, the responder rate was 12.5% (90% confidence limit, 1% to 43%) with placebo, compared to 4

58 week rotations was 0.97 (1-sided 97.5% upper confidence limit, 1.07; noninferiority P = .007).

59 hs (relative risk, 0.98; 95% one-sided upper confidence limit, 1.13; P<0.001 for noninferiority).

60 dities, and symptom (hazard ratio, 1.34; 95% confidence limit, 1.17-1.53; P<0.001).

61 ys (relative risk, 1.00; 95% one-sided upper confidence limit, 1.22; P<0.001 for noninferiority) and

62 curred after shunt implantation (upper 97.5% confidence limit, 1.5%; P<0.0001).

63 ds ratio for mortality increased by 2.2 (95% confidence limits, 1.8, 2.7).

64 Pg-Paco2 gap (mean difference, 0.03 kPa; 95% confidence limits, -1.66, 1.72) or gastric intramucosal

65 earlier gonadarche (hazard ratio = 1.23, 95% confidence limit: 1.15, 1.32) and pubarche (hazard ratio

66 1.32) and pubarche (hazard ratio = 1.44, 95% confidence limit: 1.34, 1.55), while underweight boys ha

67 ty COMT diplotypes (hazard ratio = 2.35; 95% confidence limits: 1.66, 3.32), an effect not found in s

68 difference from control 11.0%; two-sided 90% confidence limit, -11.0% to 32.9%; P=0.01 for noninferio

69 et (absolute risk difference 7.1% [upper 95% confidence limit 12.0%], p=0.42).

70 difference, 3.7 percentage points; 95% upper confidence limit, 12.56 percentage points; P=0.01 for no

71 Fourteen patients (23%; 95% lower confidence limit, 13%) achieved major cytogenetic respon

72 ; hazard ratio for PCI versus CABG=1.68, 95% confidence limits, 138-2.04; P<0.001).

73 ry for the city equal to 29 Gg/yr (5% to 95% confidence limits, 15 to 54 Gg/yr).

74 h conversion had low sensitivity (27.3% [95% confidence limit 16.6-41.4]) and high specificity (89.8%

75 8.7% vs -9.4%; difference, -8.7% [asymptotic confidence limits, -17.2% to -0.4%]; P = .04).

76 alence declined from 18.9% in 1957-1958 (95% confidence limits: 18.4%, 19.4%) to 4.9% in 2009-2012 (9

77 etween 10 mg CCX140-B and placebo (upper 95% confidence limit 2%; p=0.08).

78 vs 2%, p=0.003, OR estimate 10.32, 95% Wald confidence limits 2.04-102.46).

79 ed to a 4.7-fold increased risk for HCC (95% confidence limits = 2.2, 9.4).

80 uring the 2 yr of the study (exact 95% upper confidence limit, 2.2).

81 The study estimated that 3.34 million (95% confidence limit, 2.39-4.15 million) life-years were gai

82 ars of age had an annual risk of death of 4 (confidence limit, 2.8-5.4) times that of normal contempo

83 y thrombosis occurred in 3 patients (4%; 70% confidence limits, 2% to 7%).

84 py (hazard ratio for noncompliance=2.79; 95% confidence limits, 2.19-3.54; P<0.001; hazard ratio for

85 of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P < .001).

86 ilar mean arterial pressure (-1.1 mm Hg [95% confidence limit, -2.3, 0.2]; p(group) = 0.10), and incr

87 resulted in a naive rate ratio of 3.62 (95% confidence limits: 2.67, 4.92).

88 to 43%) with placebo, compared to 40.0% (90% confidence limit, 22% to 61%) with QAX576.

89 negative predictive value, 57% (eight of 14; confidence limits = .29, .82).

90 g2 Cryptosporidium per gram stool (95% upper confidence limit, 3.82), total stool weight decreased by

91 There were 5 hospital deaths (6%; 70% confidence limits, 3% to 10%).

92 The major response rate was 13% (95% confidence limits, 3% to 32%) for IWF A to C and 16% (95

93 fects (difference, -10.9%; 95% 1-sided upper confidence limit, -3.5; P = .01).

94 strumental-variable rate ratio was 5.02 (95% confidence limits: 3.45, 7.31), 39% higher than the naiv

95 = .72, .95); specificity, 73% (eight of 11; confidence limits = .39, .94); positive predictive value

96 d with a 9.4-fold elevation in HCC risk (95% confidence limits = 4.7, 18.7).

97 d with a 12.6-fold increase in HCC risk (95% confidence limits = 4.7, 33.6).

98 fference, 0.7 percentage points; upper 97.5% confidence limit, 4.0 percentage points; P=0.02 for noni

99 difference from control 16.4%; two-sided 90% confidence limit, -4.3% to 37.1%; P=0.002 for noninferio

100 its: 18.4%, 19.4%) to 4.9% in 2009-2012 (95% confidence limits: 4.0%, 5.8%).

101 fferences per 1000 beachgoers were 32.7 (95% confidence limits 5.7; 59.6) and 94.8 (4.6; 276), respec

102 mg CCX140-B and placebo (one-sided upper 95% confidence limit -5%; p=0.01) and a -10% difference betw

103 patients with CTDs (relative risk, 8.1; 95% confidence limit, 5.1-12.9; chi(2)1 = 112.0; P < 10(-3))

104 mits, 3% to 32%) for IWF A to C and 16% (95% confidence limits, 5% to 34%) for IWF D to H; response d

105 .0, -16.4 g), and atenolol (mean, -28.1; 95% confidence limits, -50.9, -5.3 g).

106 ute risk difference, 1.8%, upper 1-sided 95% confidence limit, 6.1%; P=0.0549 for noninferiority).

107 Amiodarone reduced total mortality by 19% (confidence limits, 6% to 31%; P<.01), with somewhat grea

108 -65.5, -20.2 g), captopril (mean, -38.7; 95% confidence limits, -61.0, -16.4 g), and atenolol (mean,

109 approximately 1000-fold higher in first (95% confidence limits, 611 to 1376) and second (95% confiden

110 rotective efficacy, 93%; lower one-sided 95% confidence limit, 62%).

111 fidence limits, 611 to 1376) and second (95% confidence limits, 633 to 1623) trimester biopsies when

112 was achieved in 48 patients (77%; 95% lower confidence limit, 65%); median response duration was 9.1

113 d with hydrochlorothiazide (mean, -42.9; 95% confidence limits, -65.5, -20.2 g), captopril (mean, -38

114 y group (difference, 1.6%; 1-sided 95% lower confidence limit, -7.6%; noninferiority P = .18).

115 Sensitivity was 86% (37 of 43; 95% confidence limits = .72, .95); specificity, 73% (eight o

116 otective efficacy, 100%; lower one-sided 95% confidence limit, 75%).

117 ile with lower heart rate (-7.0 min(-1) [95% confidence limit, -8.7, -5.1]; p(group) < 0.0001), simil

118 e plasma estradiol level was 4.3% lower (95% confidence limits, -8.3%, -0.2%) for a substitution of 5

119 ); positive predictive value, 92% (37 of 40; confidence limits = .80, .98); and negative predictive v

120 informative cases analyzed (P=2.4x10-7; 95% confidence limits 87%-100%).

121 h all-cause shock-free rate was 90.6% (lower confidence limit, 89.0%), meeting the prespecified perfo

122 teen-month freedom from IAS was 95.9% (lower confidence limit, 94.8%).

123 mated adjusted hazard ratios (aHRs) with 95% confidence limits (95% CL) for TB and mortality.

124 expected (O/E) ratios and corresponding 95% confidence limits (95% CL) of cigarette smoking were 0.7

125 h ERCC1 C8092A [hazard ratio (HR), 0.72; 95% confidence limits (95% CL), 0.60-0.86; P = 0.0004] and G

126 estimated means, odds ratios (ORs), and 95% confidence limits (95% CLs) of efficacy within COMT geno

127 e of precision as seen by the 2.5-fold wider confidence limits (95% confidence limits: 0.06, 0.43).

128 bo within 48 h (hazard ratio [HR], 1.68; 95% confidence limit [95% CL], 1.19, 2.38) and 28 and 58 day

129 19 FFPE samples showed 100% sensitivity (95% confidence limit: 96.5-100%) and 100% specificity (95% c

130 limit: 96.5-100%) and 100% specificity (95% confidence limit: 99.3-100%) compared with reference ass

131 The upper confidence limit accounts for the skewed distribution of

132 s at least 93.5% by a conservative lower 95% confidence limit; after a definitely negative test resul

133 of 5.4 teragrams CH(4) per year (95 per cent confidence limit)-an order of magnitude lower than the c

134 Results reported with 95% confidence limits and net reclassification improvement (

135 t the relationship is not linear, with large confidence limits, and EBCT may underestimate the total

136 e) the RR was 9.75 (P < 0.05, nonoverlapping confidence limits, AR = 123.9).

137 erent from one another when their respective confidence limits are estimated by jackknifing.

138 Primary effectiveness was 63.5% (57.3% lower confidence limit) at 1 year, with 8.5% patients having a

139 ge were defined as exceeding 95% test-retest confidence limits based upon the mean sensitivity using

140 edictor provided label specific regions with confidence limits between 80 and 99% for species identif

141 at approximately 10 000 years ago (with wide confidence limits), but only limited subsequent migratio

142 e determined as the mean of combinations and confidence limits by the IQR.

143 meter (amplitude and implicit time), the 95% confidence limit (CL) of test-retest variability was cal

144 5 square centimeters per gram (cm(2)/g) [68% confidence limit (CL)] (sigma(DM), self-interaction cros

145 ident rate ratio (IRR) = 0.98, p = 0.02, 95% Confidence Limits (CL) = 0.96-0.99).

146 Mean d(2,3)fs was 4.1 [95% confidence limits (CL) = 3.7, 4.5].

147 ession estimated hazard ratios (HRs) and 95% confidence limits (CL) for first-onset TMD.

148 cidence ratios (SIRs) with corresponding 95% confidence limits (CL) of HPV-associated subsequent mali

149 event after PCI (odds ratio [OR]: 4.33; 95% confidence limits (CL): 1.52 to 12.30), peak troponin T

150 e 1963 cohort (relative risk (RR) = 2.7, 95% confidence limits (CL): 1.6, 4.7) and the 1975 cohort (R

151 of graft loss (relative risk [RR] 0.90, 95% confidence limit [CL] 0.84-0.96, P<0.001), whereas TAC+A

152 us loads above 3.15 log(1)(0) copies/mL (95% confidence limit [CL] 2.73, 3.55) and paired rectal vira

153 to an absolute risk difference of -25.9 (95% confidence limit [CL], -59.5 to 2.7) and relative risk o

154 disease (GVHD) for all patients was 57% (95% confidence limit [CL], 0.28, 0.86), and 73% (95% CL, 0.4

155 of MA (adjusted risk ratio [aRR], 0.55; 95% confidence limit [CL], 0.47-0.64) or TM plus supplementa

156 blacks (relative prevalence [RP], 0.75; 95% confidence limit [CL], 0.61 to 0.94) and Hispanics (RP,

157 0-2011 (adjusted risk ratio [ARR], 0.81; 95% confidence limit [CL], 0.68-0.97), as did Hispanic patie

158 ipate in any form of screening (OR, 2.3; 95% confidence limit [CL], 1.7, 3.1) and in colonoscopy scre

159 A initiation at a given visit (RR, 4.94; 95% confidence limit [CL], 1.92 to 12.8).

160 cing a rejection episode than DSEK eyes (95% confidence limit [CL], 2.0-111; P = 0.008) and 20 times

161 ival and event-free survival were 99% (lower confidence limit [CL], 97.4%) and 93% (lower CL, 88.6%),

162 oven influenza virus infection was 0.45 (95% confidence limit [CL]: -0.02, 0.69) for influenza B and

163 ng pregnancy (relative risk [RR] = 1.83; 95% confidence limit [CL]: 1.12, 3.00), lower respiratory il

164 ants (p = 0.011, odds ratio [OR] = 2.63, 95% confidence limits [CL] = 1.25-5.56; p = 0.026, OR = 2.38

165 ediction had an average error of 1.5 dB (95% confidence limits [CL], +/-3.7 dB).

166 delay (Adjusted odds ratios [aOR], 1.25; 95% confidence limits [CL], 1.08 to 1.45).

167 progression (relative hazard [RH], 1.67; 95% confidence limits [CL], 1.20, 2.32; and RH, 1.45; CL, 1.

168 th PJS, the RR for all cancers was 15.2 (95% confidence limits [CL], 2, 19).

169 th an adjusted HR for mortality of 0.90 (95% confidence limits [CL]: 0.84 to 0.96), and an adjusted H

170 imated incidence odds ratios (IORs), and 95% confidence limits (CLs) were used for the association be

171 tral venous catheter (CVC) days [95% Poisson confidence limits (CLs): 2.12, 2.71 episodes/1000 CVC da

172 hazard ratio (aHR) with 95% upper and lower confidence limits (CLs)] with graft, patient, and other

173 Kaplan-Meier methodology with 97.5% 1-sided confidence limits compared with a 12% safety and 40% eff

174 ntent-to-treat estimate was biased with poor confidence limit coverage, but the proposed estimate was

175 timate was largely unbiased with appropriate confidence limit coverage.

176 two sequential measurements below the lower confidence limit defined the endpoint for each parameter

177 (dB) is needed to be outside the normal 95% confidence limits, depending on the size of the stimulus

178 At 100% specificity, based on the 95% confidence limits derived from Group IV, OCT exhibited 1

179 samples from infected mice, with a mean (95% confidence limits) effect size of 4.2 (2.8-5.6), when di

180 sion rates range from 0 to 190 kg/h with 95% confidence limits estimated at a factor of 10.

181 method, incorporating pairwise deletion and confidence limits estimated from 1000 replicates using b

182 ard deviations of less than 1%, close to the confidence limit estimates.

183 ferior to CBT-I at month 3 because the upper confidence limit exceeded the non-inferiority margin.

184 The upper 95% confidence limit excluded the risk found for mumps menin

185 ace of this, equations are given for the 95% confidence limits expected for a Poisson process.

186 ered non-inferior to CBT-I because the upper confidence limit fell within the non-inferiority margin.

187 particular result in an SRF with a 95% upper confidence limit for ash content marginally below the 20

188 lacebo group (difference, 3.5%; [90% 1-sided confidence limit for benefit, -0.9%]; P = .16; [97.5% 1-

189 The upper 95% confidence limit for condomless anal sex was 0.71 per 10

190 or plus raltegravir group (p=0.07; lower 95% confidence limit for difference 10.2% vs specified non-i

191 for benefit, -0.9%]; P = .16; [97.5% 1-sided confidence limit for harm, 10.2%]; P = .84).

192 rmation of the hypothesis that the lower 95% confidence limit for its sensitivity in detecting seriou

193 An upper 95% confidence limit for the between-group difference in fav

194 Therefore, the binomial upper 95% confidence limit for the failure rate of 0% is 7%.

195 Non-inferiority was defined as the upper 95% confidence limit for the hazard ratio (HR) for new WHO s

196 The 95% upper confidence limit for the mean 24-h QTc interval was 452

197 The upper confidence limit for the mortality difference was within

198 Efficacy was to be declared if the lower 90% confidence limit for the proportion of responders on QAX

199 The confidence limits for comparing the exposure using peak

200 high scenarios using the lower and upper 95% confidence limits for country population size, disease p

201 ser's input clone sequences and analyses the confidence limits for each nucleotide position and for t

202 The confidence limits for g(s) fits derived using F statisti

203 The 95% confidence limits for individual MRI measurements were +

204 rooted macrophytes, with satisfactory narrow confidence limits for more than half of the estimated pa

205 The 90% confidence limits for periostin were 35.0 and 71.1 ng/mL

206 s can be addressed by plotting or tabulating confidence limits for points on a flexible curve fitted

207 utcome is common, and the problem of setting confidence limits for risk ratios.

208 Estimates and their confidence limits for simulated data sets confirm that t

209 The 95% confidence limits for the 4.7% increase in inappropriate

210 The confidence limits for the achieved in-plane hit rate and

211 The 95% confidence limits for the measurements were +/-0.53.

212 Confidence limits for these estimates are often wide, pa

213 on index is quite good, with the average 95% confidence limits for three measurements on each PCB bei

214 er of locations that were worse than the 95% confidence limits for total deviation (r = 0.51) and pat

215 was 32.0 +/- 6.1 ng/72 h (mean +/- SD at 95% confidence limit) for a donor population representing bo

216 the age- and race-adjusted ORs and ICRs (95% confidence limits) for heavy smoking (>or=41 pack-years)

217 clinical presentation, relative hazards (95% confidence limits) for MI or death were 2.0 (1.4 to 3.2)

218 operative mortality rate was 10+/-3% (+/-70% confidence limits) for patients receiving a CVG and 15+/

219 the nonoutbreak periods, with all 95% lower confidence limits >1.

220 radiographic worsening in either cohort, and confidence limits in the analyses of vitamin D deficienc

221 fractive outcome was -0.12+0.12x2 (95% lower confidence limit [LCL], -1.94+1.06x44; 95% upper confide

222 o fMALDI-TOF/fHPLC was 0.797 +/- 0.0229 (99% confidence limit, n = 7) for a 30-mer peptide substrate

223 io fMALDI-TOF/fHPLC to 0.917 +/- 0.0184 (99% confidence limit, n = 7).

224 0 are forecasted to be 129,200 +/- 7742 (95% confidence limits) new patients, 651,330 +/- 15,874 long

225 A confidence limit of >99% was achieved for 36.2% of predi

226 patients was 0.05 (SD = 0.15), with an upper confidence limit of 0.30.

227 HIV transmission of zero, with an upper 95% confidence limit of 0.30/100 couple-years of follow-up.

228 ercept and methotrexate, since the 95% upper confidence limit of 0.41 for the difference in change in

229 of 1.12 or lower, as well as an upper 97.5% confidence limit of 1.33 or lower in the intention-to-tr

230 omprising 47% of the cohort) was 0.4% (upper confidence limit of 1.49%).

231 With an upper 95% confidence limit of 11.5% for the primary composite end

232 al dominant model, was 4%, with an upper 95% confidence limit of 31%.

233 be approximately 2.5%, with an upper 1-sided confidence limit of 4.4%.

234 sed to establish non-inferiority was a lower confidence limit of 5% for the risk difference.

235 total estimate is 393 Gg/yr with a 95% upper confidence limit of 854 Gg/yr (0.10% to 0.22% of the met

236 single dose of varenicline, with a 90% lower confidence limit of 89% occupancy for the thalamus and b

237 osition of the disc (MPD) fell below the 95% confidence limit of each eye's individual baseline range

238 op in either group (upper 95% exact binomial confidence limit of incidence for those who discontinued

239 le for certain power plants; and a lower 95% confidence limit of net calorific value (NCV) at 14.5 MJ

240 ived over 99,000 doses of Priorix (upper 95% confidence limit of risk: 1:27,000), in a regional datab

241 n of 1.6 million doses of Priorix (upper 95% confidence limit of risk: 1:437,000) in England and Wale

242 One-sided 95% lower confidence limit of the 5y-iDFS difference was -3.3%, es

243 in mean photopic monocular BCDVA (95% upper confidence limit of the difference was <0.1 logarithm of

244 nferiority was demonstrated if the upper 95% confidence limit of the difference was 10% or less.

245 urvival at 3 years was 77% and the lower 95% confidence limit of this estimate of survival was 60%.

246 18 mL/min/g and 0.01 +/- 0.11 mL/min/g, with confidence limits of +/-0.36 and +/-0.22 mL/min/g for un

247 of retinal thickness measurements showed 98% confidence limits of +/-17 microm at fixation and +/-11

248 was 0.13 mm (95% CI, 0.03-0.22 mm), with 95% confidence limits of -0.54 and 0.80 mm.

249 0.03 mm (95% CI, -0.06 to 0.12 mm), with 95% confidence limits of -0.66 and 0.71 mm.

250 elta(34)S from -5.0 per thousand, within 95% confidence limits of -14.8 per thousand to 4.1 per thous

251 41% at 1 year, and 57% at 2 years, with 95% confidence limits of 10%, 28%; 30%, 55%; and 44%, 71%, r

252 ,000 scf methane (0.4-0.7 Mg) per event (95% confidence limits of 10,000-50,000 scf/event).

253 1.11 in UC and 0.75 in CD, with upper (95%) confidence limits of 2.41 and 1.37, respectively.

254 TDRS subfield was 264.5 (22.9) mum, with 95% confidence limits of 220.8 and 311.5 mum.

255 000 scf methane (0.02-0.2 Mg) per event (95% confidence limits of 500-12,000 scf/event).

256 90% confidence interval contained within the confidence limits of 80.00% and 125.00%.

257 or daily energy intake were determined using confidence limits of agreement for energy intake/estimat

258 y described regression equation, and the 95% confidence limits of agreement with measured mean LAP ex

259 JSW measurement was reproducible (95% confidence limits of agreement) to within +/-0.5 mm.

260 ampled by bootstrapping to determine the 95% confidence limits of each measurement's repeatability.

261 MTT values were derived from the statistical confidence limits of group I data and then applied to gr

262 vidence of undue or unjust inducement (upper confidence limits of ORs for undue inducement, 1.15 and

263 0.99; P < .001 showing noninferiority; upper confidence limits of ORs for unjust inducement, 1.21 and

264 stical testing with calculation of upper 95% confidence limits of the differences between active and

265 observed incidence rates fell within the 95% confidence limits of the model estimates.

266 attachment level change (from estimated 95% confidence limits of visit 1 data) ranged from 0.52 mm t

267 ed to be accurate within 0.95 +/- 0.58% (95% Confidence Limit) of a commercial potentiostat.

268 timate of hospitalwide incidence (mean+/-95% confidence limit) of sepsis syndrome was 2.0+/-0.16 case

269 d controls coupled with rigorous statistical confidence limits offer a new path toward investigating

270 nd itself easily to acceptable estimation of confidence limits on the estimated concentrations.

271 Because of the wide confidence limits on the mutation rates of these loci, t

272 was estimated to be 2.05 x 10(-5) (upper 95% confidence limit) or 4.75 x 10(-6) (50% confidence limit

273 49% versus 13.86%-19.59%, respectively, (95% confidence limit; P < 0.0001).

274 95% confidence limit) or 4.75 x 10(-6) (50% confidence limit) point mutations per nucleotide per yea

275 w are -0.50 +/- 0.54 and -0.79 +/- 0.65 (95% confidence limit) ppbv yr(-1), respectively, which corre

276 lack women living in these counties, and the confidence limit ratios indicated fairly consistent leve

277 ratio of 0.84 (95% CI, 0.47-1.50); the upper confidence limit remained below the predefined noninferi

278 /-2.4) kcal/mol was recovered using rigorous confidence limit testing.

279 effects estimates that provide more accurate confidence limits than the DL estimator.

280 .2 +/- 8.8% less DNA (N = 3 individuals, 93% confidence limit) than control cultures after 3 weeks of

281 As a remedy, this report proposes lower confidence limits that account for the multiple comparis

282 Hazard ratios are presented with 95% confidence limits that are not adjusted for multiple com

283 ons to compute numeric approximations of the confidence limits that do not require the use of any pro

284 ecause of the small number of cases and wide confidence limits, the data regarding amyotrophic latera

285 With 95% confidence limits, they should allow better discriminati

286 idence limit [LCL], -1.94+1.06x44; 95% upper confidence limit [UCL], +0.77+1.05x140).

287 The one-sided lower 97.5% confidence limit was 76%, which was greater than the pre

288 behavioral indifference curves within their confidence limits, was indistinguishable between differe

289 nd -19.7 to 16.7%, respectively, and the 95% confidence limits were -18.4 to 24.2% and -18.6 to +17.3

290 One-sided 95% lower confidence limits were 0.83 (RMDQ) and 0.97 (pain), demo

291 ( r=0.80, P<0.001) and the Bland-Altman 95% confidence limits were between -0.14 and 0.12.

292 versus baseline periods across arms, but the confidence limits were broad, and the results should be

293 r estimated measurement uncertainty, and 95% confidence limits were calculated, with a null hypothesi

294 e compared by using a chi2 analysis, and 95% confidence limits were calculated.

295 diography correlated well (r = .93), and 95% confidence limits were determined.

296 s and SvO2 were compared, the ranges and 95% confidence limits were found to be clinically unacceptab

297 ne ED50 values (expressed as mg/kg, with 95% confidence limits) were: 10.2 (7.8-13.3), 1.4 (0.8-2.4)

298 hat will obtain the tightest reproducibility confidence limits, which, for a fixed total number of ex

299 h was found to be in good agreement at a 95% confidence limit with the certified value.

300 These wide range differences and confidence limits would lead to large errors if superior